Diabetes May Increase Women’s Risk Of Developing Colorectal Cancer

BY KERRI WACHTER  
Senior Writer

D iabetes may significantly increase a woman’s risk of developing colorectal cancer, according to the findings from a study involving more than 45,000 women across the United States.

“There was about a 50% increased risk of colorectal cancer in women with diabetes,” said Andrew Flood, Ph.D., a professor of epidemiology and community health at the University of Minnesota in Minneapolis.

Dr. Flood presented study findings at a press briefing held in conjunction with the annual international conference of the American Association for Cancer Research.

Dr. Flood and his colleagues prospectively analyzed data from the Breast Cancer Detection Demonstration Project follow-up cohort study. From 1987 to 1989, 45,519 women without a history of colorectal cancer completed a series of questionnaires that assessed dietary and other health and lifestyle risk factors for colorectal cancer. The average age at the time of the interview was 62 years. On average, the time between the baseline and follow-up was 9 years, during which time 489 women developed colorectal cancer. After the researchers controlled for age, physical activity, energy intake, alcohol consumption, hormone therapy, smoking, multivitamin use, education, ethnicity, NSAID use, calcium supplementation, and calcium intake from diet, women with diabetes at baseline had an adjusted hazard ratio (HR) of 1.50 for developing colorectal cancer.

The researchers hypothesized that the elevated levels of insulin typically seen in people with type 2 diabetes may play a central role. Insulin stimulates the growth of normal colonic and carcinoma cells. Insulin also modulates insulin-like growth factor 1 (IGF-1) and its binding proteins, creating a promitotic environment for colonic epithelial cells. Insulin is chronically elevated in prediabetes and in diabetes until the pancreas becomes unable to keep up with the body’s need for insulin.

When the researchers conducted a second analysis that included women who were likely prediabetic at baseline, according to self reports at the 1993-1995 follow-up, the multivariate adjusted HR for developing colorectal cancer was slightly lower (1.36) in this population of women. Among the prediabetic women, the degree of hyperinsulinemia may not have been of a sufficient magnitude or of a sufficient duration to increase the risk of colorectal cancer, the researchers speculated. Alternatively, there may be some factor related to diabetes, independent of hyperinsulinemia, that is driving the observed increase in colorectal cancer risk among the diabetic women.

■

Spanish Language Web Site From CDC

The Centers for Disease Control and Prevention has relaunched its Spanish language Web site, CDC en Español, with new features. The site provides up-to-date information on health promotion and disease prevention topics of special interest to Hispanic communities, including asthma, cancer, HIV/AIDS, immunizations, children’s health, diabetes, and occupational hazards. CDC en Español receives more than 6 million visitors a year. The Web site address is www.cdc.gov/spanish.

To get fast glucose control, add NovoLog®
For patients not at goal on basal insulin, NovoLog®:
• Mimics the body’s normal mealtime insulin response
• Provides significantly better mean PPG* levels than regular human insulin
• Offers convenient mealtime dosing in the patient-preferred FlexPen**

■

NovoLog® is indicated for the treatment of patients with diabetes mellitus for the control of hyperglycemia.

Important safety information
NovoLog® has a more rapid onset and shorter duration of action than regular human insulin. Because of the fast onset of action, the injection of NovoLog should be immediately followed by a meal. Because of the short duration of action of NovoLog, patients with diabetes also require a long-acting insulin to maintain adequate glucose control. NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients. Hypoglycemia is the most common adverse effect of insulin therapy, including NovoLog®. Any change in insulin should be made cautiously and only under medical supervision.

Please see brief summary of prescribing information on adjacent page.

Call 1-800-227-4500 or visit novolog.com.

* PPG = post-prandial plasma glucose.
** Notion and FlexPen are registered trademarks of Novo Nordisk A/S.
© 2007 Novo Nordisk Inc. 15009 1/06/07

Novo Log®
Insulin aspart (DNA origin) injection
Rapid, Flexible control**